Citius Pharmaceuticals, Inc. (CTXR)Healthcare | Biotechnology | Cranford, United States | NasdaqCM
0.54 USD
-0.04
(-7.328%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:55 a.m. EDT
The investment case for Citius Pharmaceuticals is currently broken by a catastrophic multi-year price collapse and a lack of fundamental traction. While the company has achieved a commercial launch for LYMPHIR, the market has punished the stock relentlessly, wiping out over 99% of its value since 2016. The recent price action shows a stock trading well below its 50-day and 200-day averages, confirming a persistent downtrend. Crucially, the options market is screaming 'sell'; the heavy concentration of put open interest suggests investors are betting hard against any recovery, viewing the current price as a continuation of the decline rather than a bottom. With negative free cash flow, negative operating margins, and a balance sheet that requires constant capital raising (evidenced by the recent $5M offering), the business faces severe liquidity and execution risks. The statistical forecast model offers no help, showing a weak lean to the downside with low confidence. This is a speculative trap where the narrative of a 'breakeven horizon' clashes violently with the reality of a stock in freefall. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.106917 |
| AutoTheta | 0.108934 |
| MSTL | 0.128816 |
| AutoARIMA | 0.283826 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 3.35 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.148 |
| Excess Kurtosis | -1.32 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.17 |
| Revenue per Share | 0.311 |
| Market Cap | 14,824,388 |
| Forward P/E | -0.67 |
| Beta | 0.98 |
| Website | https://citiuspharma.com |
As of July 11, 2026, 3:55 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest significantly exceeds call open interest across all expirations, with deep out-of-the-money puts showing massive volume relative to calls. This indicates a strong consensus among retail traders that the stock will trade lower, despite the company's recent commercial launch news.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6508982 |
| Address1 | 11 Commerce Drive |
| Address2 | First Floor |
| All Time High | 937.5 |
| All Time Low | 0.476 |
| Ask | 0.7112 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 191,080 |
| Average Daily Volume3 Month | 626,855 |
| Average Volume | 626,855 |
| Average Volume10Days | 191,080 |
| Beta | 0.981 |
| Bid | 0.3966 |
| Bid Size | 2 |
| Book Value | 2.75 |
| City | Cranford |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.54 |
| Current Ratio | 0.576 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.58 |
| Day Low | 0.54 |
| Debt To Equity | 1.17 |
| Display Name | Citius Pharmaceuticals |
| Dividend Date | 1,496,966,400 |
| Earnings Timestamp | 1,778,875,200 |
| Earnings Timestamp End | 1,786,737,600 |
| Earnings Timestamp Start | 1,786,737,600 |
| Ebitda | -53,851,096 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.345 |
| Enterprise To Revenue | 3.312 |
| Enterprise Value | 18,585,392 |
| Eps Current Year | -1.87 |
| Eps Forward | -0.81 |
| Eps Trailing Twelve Months | -1.98 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.60782 |
| Fifty Day Average Change | -0.06781995 |
| Fifty Day Average Change Percent | -0.111579016 |
| Fifty Two Week Change Percent | -65.08982 |
| Fifty Two Week High | 2.19 |
| Fifty Two Week High Change | -1.6500001 |
| Fifty Two Week High Change Percent | -0.7534247 |
| Fifty Two Week Low | 0.476 |
| Fifty Two Week Low Change | 0.06400001 |
| Fifty Two Week Low Change Percent | 0.1344538 |
| Fifty Two Week Range | 0.476 - 2.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,412,256,600,000 |
| Float Shares | 26,959,796 |
| Forward Eps | -0.81 |
| Forward P E | -0.6666667 |
| Free Cashflow | -33,459,172 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 23 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.80074996 |
| Gross Profits | 4,493,323 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01795 |
| Held Percent Institutions | 0.036310002 |
| Implied Shares Outstanding | 27,452,570 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Last Split Date | 1,732,579,200 |
| Last Split Factor | 1:25 |
| Long Business Summary | Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. |
| Long Name | Citius Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 14,824,388 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_272471835 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -46,201,084 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 22,626,214 |
| Number Of Analyst Opinions | 1 |
| Open | 0.58 |
| Operating Cashflow | -31,596,252 |
| Operating Margins | -18.27776 |
| Payout Ratio | 0.0 |
| Phone | 908 967 6677 |
| Previous Close | 0.5827 |
| Price Eps Current Year | -0.28877005 |
| Price Hint | 4 |
| Price To Book | 0.19636364 |
| Price To Sales Trailing12 Months | 2.64183 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.103 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0427 |
| Regular Market Change Percent | -7.32795 |
| Regular Market Day High | 0.58 |
| Regular Market Day Low | 0.54 |
| Regular Market Day Range | 0.54 - 0.58 |
| Regular Market Open | 0.58 |
| Regular Market Previous Close | 0.5827 |
| Regular Market Price | 0.54 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 257,824 |
| Return On Assets | -0.27628002 |
| Return On Equity | -0.83599 |
| Revenue Per Share | 0.311 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 27,452,570 |
| Shares Percent Shares Out | 0.1735 |
| Shares Short | 4,763,787 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,948,323 |
| Short Name | Citius Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1767 |
| Short Ratio | 17.48 |
| Source Interval | 15 |
| State | NJ |
| Symbol | CTXR |
| Target High Price | 4.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.0 |
| Target Median Price | 4.0 |
| Total Cash | 4,590,174 |
| Total Cash Per Share | 0.167 |
| Total Debt | 808,162 |
| Total Revenue | 5,611,409 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.98 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.91196 |
| Two Hundred Day Average Change | -0.37195998 |
| Two Hundred Day Average Change Percent | -0.40786874 |
| Type Disp | Equity |
| Volume | 257,824 |
| Website | https://citiuspharma.com |
| Zip | 7,016 |